Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported multiple equity award vestings and related share movements in Class A Common Stock and restricted stock units.
On March 3, 2026, performance-based restricted stock units granted on March 3, 2023 were certified at 200% of the targeted number, resulting in the vesting and settlement of 305,810 performance-based restricted stock units into an equal number of Class A Common Stock shares on a one-for-one basis, with a portion of the resulting shares withheld to satisfy tax obligations. Additional time-based restricted stock units granted on March 3, 2022, March 3, 2023, March 4, 2024 and March 3, 2025 vested in scheduled installments and were converted into Class A Common Stock, again with some shares withheld for taxes.
Following these transactions, Daly held 251,784 shares of Class A Common Stock directly as of March 4, 2026, along with 71,760 restricted stock units, reflecting ongoing equity-based compensation rather than open-market purchases or sales.
Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported multiple equity award vestings and related share issuances. On March 3 and 4, 2026, restricted stock units and performance-based restricted stock units were exercised and converted into shares of Class A Common Stock at no exercise price.
A performance-based grant of 458,716 performance-based restricted stock units from a March 3, 2023 award vested at 200% of its targeted amount after share-price conditions were met and was settled one-for-one into Class A shares. Across the transactions, portions of the newly issued shares, including amounts such as 229,817 shares at $13.31 and other blocks at prices around $13.30–$13.31, were withheld to cover tax withholding obligations, rather than sold in open-market trades. Following these events, Konidaris directly held 449,434 shares of Class A Common Stock as of the latest reported transaction.
Amneal Pharmaceuticals, Inc. Executive Vice President Andrew S. Boyer reported multiple equity award vestings and related share transfers. On March 3, 2026, performance-based restricted stock units, including 397,554 performance-based RSUs, were certified as having met their performance threshold and vested, then settled into an equal number of Class A Common Stock shares on a one-for-one basis. Several time-based restricted stock unit grants also vested and were settled into Class A Common Stock.
To cover tax withholding obligations tied to these vestings, Boyer had blocks of Class A Common Stock withheld, including 199,175 shares at $13.31 per share and 19,136 shares at $13.30 per share, classified as tax-withholding dispositions. Following the transactions on March 4, 2026, Boyer directly held 426,072 shares of Amneal Class A Common Stock.
Amneal Pharmaceuticals Executive Vice President Nikita Shah reported multiple equity award vestings and related share withholdings. On March 3, 2026, performance-based restricted stock units granted in 2023 were certified above target, vesting at 200% of the targeted number and settling into an equal number of Class A shares.
Across March 3–4, 2026, Shah acquired Class A Common Stock through exercises and conversions of restricted stock units and performance-based units, while a portion of the resulting shares was automatically disposed of at prices around $13.30 per share to satisfy tax withholding obligations.
Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Co-CEO Chintu Patel reported equity awards of restricted stock units. On March 2, 2026, he received 190,632 restricted stock units, each representing a contingent right to one share of Class A common stock, vesting in four equal annual installments beginning March 2, 2027.
He was also granted 354,031 performance-based restricted stock units tied to average closing price targets over a three-year performance period. The award can pay out from 0% to 200% of the 354,031 target shares, with any earned units vesting in full on February 28, 2029, representing the maximum number of shares issuable under this grant.
Patel Chirag K. reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that President and Co-CEO Chirag K. Patel received equity awards in the form of restricted stock units. He was granted 190,632 time-based restricted stock units, each representing a right to receive one share of Class A common stock, vesting in four equal annual installments beginning on March 2, 2027.
He also received 354,031 performance-based restricted stock units, tied to the company’s average closing share price over a three-year performance period. The number of shares ultimately delivered may range from 0% to 200% of the target, with any earned units vesting in full on February 28, 2029, and the table reflecting the maximum shares issuable.
Shah Nikita reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Executive Vice President Nikita Shah received equity awards in the form of restricted stock units. She was granted 65,359 time-based restricted stock units and 65,359 performance-based restricted stock units, each representing a right to receive one share of Class A common stock.
The time-based units vest in four equal annual installments starting on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year performance period, with potential payout from 0% to 200% of the target, and any earned units vesting on February 28, 2029.
Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported equity awards of restricted stock units. He acquired 72,622 time-based restricted stock units and 72,622 performance-based restricted stock units, each representing a contingent right to receive one share of Amneal’s Class A common stock.
The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based restricted stock units are tied to Amneal’s average closing share price over a three-year performance period and can pay out from 0% to 200% of the 72,622 target shares, with any earned units vesting in full on February 28, 2029.
Daly Jason B. reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that EVP and Chief Legal Officer Jason B. Daly received two equity awards on March 2, 2026. He was granted 65,359 restricted stock units that vest in four equal annual installments beginning March 2, 2027. He also received 65,359 performance-based restricted stock units tied to three-year stock price targets, with any earned units vesting on February 28, 2029.
BOYER ANDREW S reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer reported awards of 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Class A common stock if vesting conditions are met.
The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year period ending February 28, 2029, with payout ranging from 0% to 200% of a 65,359-share target and a maximum of 65,359 shares issuable under the award.